Glofitamab
id:
glofitamab-162-12838682
title:
Glofitamab
text:
Glofitamab, sold under the brand name Columvi, is a bispecific monoclonal antibody used for the treatment of large B-cell lymphoma. It is a bispecific CD20-directed CD3 T-cell engager developed by Roche. The most common side effects include cytokine release syndrome, muscle and bone pain, rash, and tiredness. It was approved for medical use in Canada in July 2023, in the United States in June 2023, and in the European Union in July 2023.
brand slug:
wiki
category slug:
encyclopedia
description:
Medication
original url:
https://en.wikipedia.org/wiki/Glofitamab
date created:
2023-04-25T03:52:40Z
date modified:
2024-08-27T20:02:51Z
main entity:
{"identifier":"Q117846135","url":"https://www.wikidata.org/entity/Q117846135"}
image:
fields total:
13
integrity:
15